Amgen targets rare diseases with acquisition

After a period of high M&A activity in the biotech sector, 2022 has been a relatively slow year. Now, American Amgen rounds off the year with an acquisition of sector colleague Horizon Therapeutics worth 28 BUSD. With the acquisition, Amgen is targeting the rare disease market.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/amgen-targets-rare-diseases-with-acquisition/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se